1887

Abstract

Otitis media (OM) is a common disease affecting humans, especially paediatric populations. OM refers to inflammation of the middle ear and can be broadly classified into two types, acute and chronic. Bacterial infection is one of the most common causes of OM. Despite the introduction of vaccines, the incidence of OM remains significantly high worldwide. In this mini-review article, we discuss the recent treatment modalities for OM, such as suspension gel, transcutaneous immunization, and intranasal and transtympanic drug delivery, including therapies that are currently undergoing clinical trials. We provide an overview of how these recent advancements in therapeutic strategies can facilitate the circumvention of current treatment challenges involving preadolescence soft palate dysfunction, biofilm formation, tympanic membrane (ear drum) barrier and the attainment of efficacious drug concentrations in the middle ear. While traditional first-line immunization strategies are generally not very efficacious against biofilms, new technologies that use transdermal or intranasal drug delivery via chitosan–PsaA nanoparticles have shown promising results in experimental animal models of OM. Sustained drug delivery systems such as penta-block copolymer poloxamer 407–polybutylphosphoester (P407-PBP) or poloxamer 407 (e.g. OTO-201, with the brand name ‘OTIPRIO’) have demonstrated that treatments can be reduced to a single topical application. The emergence of effective new treatment modalities opens up promising new avenues for the treatment of OM that could lead to improved quality of life for many children and their families.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000810
2018-08-07
2020-01-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/10/1417.html?itemId=/content/journal/jmm/10.1099/jmm.0.000810&mimeType=html&fmt=ahah

References

  1. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A et al. The diagnosis and management of acute otitis media. Pediatrics 2013;131:e964e999 [CrossRef][PubMed]
    [Google Scholar]
  2. Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998;279:875–877 [CrossRef][PubMed]
    [Google Scholar]
  3. Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010;304:2161–2169 [CrossRef][PubMed]
    [Google Scholar]
  4. Rosenfeld RM, Shin JJ, Schwartz SR, Coggins R, Gagnon L et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngol Head Neck Surg 2016;154:S1–S41 [CrossRef][PubMed]
    [Google Scholar]
  5. Buzatto GP, Tamashiro E, Proenca-Modena JL, Saturno TH, Prates MC et al. The pathogens profile in children with otitis media with effusion and adenoid hypertrophy. PLoS One 2017;12:e0171049 [CrossRef][PubMed]
    [Google Scholar]
  6. Verhoeff M, van der Veen EL, Rovers MM, Sanders EA, Schilder AG. Chronic suppurative otitis media: a review. Int J Pediatr Otorhinolaryngol 2006;70:1–12 [CrossRef][PubMed]
    [Google Scholar]
  7. Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998;42:207–223 [CrossRef][PubMed]
    [Google Scholar]
  8. Mittal R, Lisi CV, Gerring R, Mittal J, Mathee K et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media. J Med Microbiol 2015;64:1103–1116 [CrossRef][PubMed]
    [Google Scholar]
  9. Schilder AG, Chonmaitree T, Cripps AW, Rosenfeld RM, Casselbrant ML et al. Otitis media. Nat Rev Dis Primers 2016;2:16063 [CrossRef][PubMed]
    [Google Scholar]
  10. Khattak SF, Sheikh NA, Aleem A, Farooq M, Nadeem K. Microbiological profile from middle ear and nasopharynx in patients suffering from chronic active mucosal otitis media. J Ayub Med Coll Abbottabad 2017;29:610–613[PubMed]
    [Google Scholar]
  11. Rath S, Das SR, Padhy RN. Surveillance of bacteria Pseudomonas aeruginosa and MRSA associated with chronic suppurative otitis media. Braz J Otorhinolaryngol 2017;83:201–206 [CrossRef][PubMed]
    [Google Scholar]
  12. Song JJ, Lee BD, Lee KH, Lee JD, Park YJ et al. Changes in antibiotic resistance in recurrent Pseudomonas aeruginosa infections of chronic suppurative otitis media. Ear Nose Throat J 2016;95:446–451[PubMed]
    [Google Scholar]
  13. Mittal R, Grati M, Gerring R, Blackwelder P, Yan D et al. In vitro interaction of Pseudomonas aeruginosa with human middle ear epithelial cells. PLoS One 2014;9:e91885 [CrossRef][PubMed]
    [Google Scholar]
  14. Mittal R, Grati M, Yan D, Liu XZ. Pseudomonas aeruginosa activates PKC-alpha to invade middle ear epithelial cells. Front Microbiol 2016;7:255 [CrossRef][PubMed]
    [Google Scholar]
  15. Mittal R, Lisi CV, Kumari H, Grati M, Blackwelder P et al. Otopathogenic Pseudomonas aeruginosa enters and survives inside macrophages. Front Microbiol 2016;7:7 [CrossRef][PubMed]
    [Google Scholar]
  16. Prakash R, Juyal D, Negi V, Pal S, Adekhandi S et al. Microbiology of chronic suppurative otitis media in a tertiary care setup of uttarakhand state, India. N Am J Med Sci 2013;5:282–287 [CrossRef][PubMed]
    [Google Scholar]
  17. Brook I. Role of anaerobic bacteria in chronic otitis media and cholesteatoma. Int J Pediatr Otorhinolaryngol 1995;31:153–157 [CrossRef][PubMed]
    [Google Scholar]
  18. Brook I. The role of anaerobic bacteria in chronic suppurative otitis media in children: implications for medical therapy. Anaerobe 2008;14:297–300 [CrossRef][PubMed]
    [Google Scholar]
  19. Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep 2012;12:551–558 [CrossRef][PubMed]
    [Google Scholar]
  20. Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J et al. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol 2011;49:3750–3755 [CrossRef][PubMed]
    [Google Scholar]
  21. Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther 2016;21:27–35 [CrossRef][PubMed]
    [Google Scholar]
  22. Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics 2017;140:e20170181 [CrossRef][PubMed]
    [Google Scholar]
  23. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989;160:83–94 [CrossRef][PubMed]
    [Google Scholar]
  24. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004;23:824–828 [CrossRef][PubMed]
    [Google Scholar]
  25. Klein JO, Pelton S. Acute otitis media in children: treatment. In Edwards MS, Isaacson GC, Torchia MM. (editors) UpToDate Waltham, MA: UpToDate; 2018
    [Google Scholar]
  26. Klein JO. Review of consensus reports on management of acute otitis media. Pediatr Infect Dis J 1999;18:1152–1155 [CrossRef][PubMed]
    [Google Scholar]
  27. Harrison CJ. Amoxicillin is the most cost-effective therapy for acute otitis media: the culmination of 40 years of research. J Pediatr 2017;189:5–8 [CrossRef][PubMed]
    [Google Scholar]
  28. Coates H, Thornton R, Langlands J, Filion P, Keil AD et al. The role of chronic infection in children with otitis media with effusion: evidence for intracellular persistence of bacteria. Otolaryngol Head Neck Surg 2008;138:778–781 [CrossRef][PubMed]
    [Google Scholar]
  29. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006;296:202–211 [CrossRef][PubMed]
    [Google Scholar]
  30. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A et al. The diagnosis and management of acute otitis media. Pediatrics 2013;131:e964e999 [CrossRef][PubMed]
    [Google Scholar]
  31. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM. Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2013;31:CD000219
    [Google Scholar]
  32. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302:758–766 [CrossRef][PubMed]
    [Google Scholar]
  33. Brixner DI. Improving acute otitis media outcomes through proper antibiotic use and adherence. Am J Manag Care 2005;11:S202–210[PubMed]
    [Google Scholar]
  34. Sun D, McCarthy TJ, Liberman DB. Cost-effectiveness of watchful waiting in acute otitis media. Pediatrics 2017;139:e20163086 [CrossRef][PubMed]
    [Google Scholar]
  35. Haggard M. Poor adherence to antibiotic prescribing guidelines in acute otitis media-obstacles, implications, and possible solutions. Eur J Pediatr 2011;170:323–332 [CrossRef][PubMed]
    [Google Scholar]
  36. Rettig E, Tunkel DE. Contemporary concepts in management of acute otitis media in children. Otolaryngol Clin North Am 2014;47:651–672 [CrossRef][PubMed]
    [Google Scholar]
  37. Stol K, Verhaegh SJ, Graamans K, Engel JA, Sturm PD et al. Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion. Int J Pediatr Otorhinolaryngol 2013;77:488–493 [CrossRef][PubMed]
    [Google Scholar]
  38. Chiu NC, Lin HY, Hsu CH, Huang FY, Lee KS et al. Epidemiological and microbiological characteristics of culture-proven acute otitis media in Taiwanese children. J Formos Med Assoc 2012;111:536–541 [CrossRef][PubMed]
    [Google Scholar]
  39. Brook I, Gober AE. Reliability of the microbiology of spontaneously draining acute otitis media in children. Pediatr Infect Dis J 2000;19:571–573 [CrossRef][PubMed]
    [Google Scholar]
  40. Saukkoriipi A, Palmu A, Kilpi T, Leinonen M. Real-time quantitative PCR for the detection of Streptococcus pneumoniae in the middle ear fluid of children with acute otitis media. Mol Cell Probes 2002;16:385–390 [CrossRef][PubMed]
    [Google Scholar]
  41. Rasmussen R. Quantification on the light-cycler. In Meuer S, Wittwer C, Nakagawara K. (editors) Rapid Cycle Real-time PCR Methods and Applications Berlin Heidelberg: Springer Verlag; 2001; pp.21–34
    [Google Scholar]
  42. Rybak A, Levy C, Bonacorsi S, Béchet S, Vié Le Sage F et al. Antibiotic resistance of potential otopathogens isolated from nasopharyngeal flora of children with acute otitis media before, during and after pneumococcal conjugate vaccines implementation. Pediatr Infect Dis J 2018;37:e72e78 [CrossRef][PubMed]
    [Google Scholar]
  43. Sarasoja I, Jokinen J, Lahdenkari M, Kilpi T, Palmu AA. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J 2013;32:517–520 [CrossRef][PubMed]
    [Google Scholar]
  44. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 2012;12:207 [CrossRef][PubMed]
    [Google Scholar]
  45. Massa HM, Cripps AW, Lehmann D. Otitis media: viruses, bacteria, biofilms and vaccines. Med J Aust 2009;191:S44–49[PubMed]
    [Google Scholar]
  46. Dupont D, Mahjoub-Messai F, François M, Doit C, Mariani-Kurkdjian P et al. Evolving microbiology of complicated acute otitis media before and after introduction of the pneumococcal conjugate vaccine in France. Diagn Microbiol Infect Dis 2010;68:89–92 [CrossRef][PubMed]
    [Google Scholar]
  47. Pumarola F, Marès J, Losada I, Minguella I, Moraga F et al. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol 2013;77:1231–1236 [CrossRef][PubMed]
    [Google Scholar]
  48. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010;29:304–309 [CrossRef][PubMed]
    [Google Scholar]
  49. Ngo CC, Massa HM, Thornton RB, Cripps AW. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One 2016;11:e0150949 [CrossRef][PubMed]
    [Google Scholar]
  50. Limb CJ, Lustig LR, Klein JO. Acute otitis media in adults. In Deschler DG, Sullivan DJ. (editors) UpToDate Welthem, MA: UpToDate; 2018
    [Google Scholar]
  51. Das J, Mokrzan E, Lakhani V, Rosas L, Jurcisek JA et al. Extracellular DNA and type IV pilus expression regulate the structure and kinetics of biofilm formation by nontypeable Haemophilus influenzae. MBio 2017;8:e01466-17 [CrossRef][PubMed]
    [Google Scholar]
  52. Cuevas RA, Eutsey R, Kadam A, West-Roberts JA, Woolford CA et al. A novel streptococcal cell-cell communication peptide promotes pneumococcal virulence and biofilm formation. Mol Microbiol 2017;105:554–571 [CrossRef][PubMed]
    [Google Scholar]
  53. Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 2012;272:541–561 [CrossRef][PubMed]
    [Google Scholar]
  54. Coticchia JM, Chen M, Sachdeva L, Mutchnick S. New paradigms in the pathogenesis of otitis media in children. Front Pediatr 2013;1:52 [CrossRef][PubMed]
    [Google Scholar]
  55. Hoa M, Syamal M, Schaeffer MA, Sachdeva L, Berk R et al. Biofilms and chronic otitis media: an initial exploration into the role of biofilms in the pathogenesis of chronic otitis media. Am J Otolaryngol 2010;31:241–245 [CrossRef][PubMed]
    [Google Scholar]
  56. Marcuzzo AV, Tofanelli M, Boscolo Nata F, Gatto A, Tirelli G. Hyaluronate effect on bacterial biofilm in ENT district infections: a review. APMIS 2017;125:763–772 [CrossRef][PubMed]
    [Google Scholar]
  57. Tawfik SA, Ibrahim AA, Talaat IM, El-Alkamy SS, Youssef A. Role of bacterial biofilm in development of middle ear effusion. Eur Arch Otorhinolaryngol 2016;273:4003–4009 [CrossRef][PubMed]
    [Google Scholar]
  58. Vlastarakos PV, Nikolopoulos TP, Maragoudakis P, Tzagaroulakis A, Ferekidis E. Biofilms in ear, nose, and throat infections: how important are they?. Laryngoscope 2007;117:668–673 [CrossRef][PubMed]
    [Google Scholar]
  59. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol Head Neck Surg 2002;128:1129–1133 [CrossRef][PubMed]
    [Google Scholar]
  60. Post JC. Direct evidence of bacterial biofilms in otitis media. Laryngoscope 2001;111:2083–2094 [CrossRef][PubMed]
    [Google Scholar]
  61. Edmunds AL. Otiprio: an FDA-approved ciprofloxacin suspension gel for pediatric otitis media with effusion. P T 2017;42:307–311[PubMed]
    [Google Scholar]
  62. Dohar J, Giles W, Roland P, Bikhazi N, Carroll S et al. Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea through tympanostomy tubes. Pediatrics 2006;118:e561e569 [CrossRef][PubMed]
    [Google Scholar]
  63. Novotny LA, Clements JD, Goodman SD, Bakaletz LO. Transcutaneous immunization with a band-aid prevents experimental otitis media in a polymicrobial model. Clin Vaccine Immunol 2017;24:e00563-16 [CrossRef][PubMed]
    [Google Scholar]
  64. Boyd NH, Gottschall JA. Assessing the efficacy of tragal pumping: a randomized controlled trial. Otolaryngol Head Neck Surg 2011;144:891–893 [CrossRef][PubMed]
    [Google Scholar]
  65. Marchisio P, Bellussi L, Di Mauro G, Doria M, Felisati G et al. Acute otitis media: From diagnosis to prevention. Summary of the Italian guideline. Int J Pediatr Otorhinolaryngol 2010;74:1209–1216 [CrossRef][PubMed]
    [Google Scholar]
  66. Block SL, Heikkinen T, Toback SL, Zheng W, Ambrose CS. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011;30:203–207 [CrossRef][PubMed]
    [Google Scholar]
  67. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–696 [CrossRef][PubMed]
    [Google Scholar]
  68. Yu J, Zhang Y, Kahkoska AR, Gu Z. Bioresponsive transcutaneous patches. Curr Opin Biotechnol 2017;48:28–32 [CrossRef][PubMed]
    [Google Scholar]
  69. Ita K. Transdermal delivery of vaccines – recent progress and critical issues. Biomed Pharmacother 2016;83:1080–1088 [CrossRef][PubMed]
    [Google Scholar]
  70. Levine MM. "IDEAL" vaccines for resource poor settings. Vaccine 2011;29:D116–D125 [CrossRef][PubMed]
    [Google Scholar]
  71. Novotny LA, Bakaletz LO. Intercellular adhesion molecule 1 serves as a primary cognate receptor for the Type IV pilus of nontypeable Haemophilus influenzae. Cell Microbiol 2016;18:1043–1055 [CrossRef][PubMed]
    [Google Scholar]
  72. Xu JH, Dai WJ, Chen B, Fan XY. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae. Scand J Immunol 2015;81:177–185 [CrossRef][PubMed]
    [Google Scholar]
  73. Cripps AW, Kyd JM. Comparison of mucosal and parenteral immunisation in two animal models of pneumococcal infection: otitis media and acute pneumonia. Vaccine 2007;25:2471–2477 [CrossRef][PubMed]
    [Google Scholar]
  74. Kim BG, Kang IJ. Evaluation of the effects of biodegradable nanoparticles on a vaccine delivery system using AFM, SEM, and TEM. Ultramicroscopy 2008;108:1168–1173 [CrossRef][PubMed]
    [Google Scholar]
  75. Sabirov A, Metzger DW. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 2008;26:1566–1576 [CrossRef][PubMed]
    [Google Scholar]
  76. Rosenfeld RM, Schwartz SR, Pynnonen MA, Tunkel DE, Hussey HM et al. Clinical practice guideline: tympanostomy tubes in children. Otolaryngol Head Neck Surg 2013;149:S1–35 [CrossRef][PubMed]
    [Google Scholar]
  77. Heslop A, Lildholdt T, Gammelgaard N, Ovesen T. Topical ciprofloxacin is superior to topical saline and systemic antibiotics in the treatment of tympanostomy tube otorrhea in children: the results of a randomized clinical trial. Laryngoscope 2010;120:2516–2520 [CrossRef][PubMed]
    [Google Scholar]
  78. Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA et al. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988;35:373–447[PubMed]
    [Google Scholar]
  79. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009;34:349–357 [CrossRef][PubMed]
    [Google Scholar]
  80. Kurabi A, Pak KK, Bernhardt M, Baird A, Ryan AF. Discovery of a biological mechanism of active transport through the tympanic membrane to the middle ear. Sci Rep 2016;6:22663 [CrossRef][PubMed]
    [Google Scholar]
  81. Kurabi A, Beasley KA, Chang L, McCann J, Pak K et al. Peptides actively transported across the tympanic membrane: Functional and structural properties. PLoS One 2017;12:e0172158 [CrossRef][PubMed]
    [Google Scholar]
  82. Kurabi A, Schaerer D, Chang L, Pak K, Ryan AF. Optimisation of peptides that actively cross the tympanic membrane by random amino acid extension: a phage display study. J Drug Target 2018;26:127–134 [CrossRef][PubMed]
    [Google Scholar]
  83. Yang R, Sabharwal V, Okonkwo OS, Shlykova N, Tong R et al. Treatment of otitis media by transtympanic delivery of antibiotics. Sci Transl Med 2016;8:356ra120 [CrossRef][PubMed]
    [Google Scholar]
  84. Oxley KS, Thomas JG, Ramadan HH. Effect of ototopical medications on tympanostomy tube biofilms. Laryngoscope 2007;117:1819–1824 [CrossRef][PubMed]
    [Google Scholar]
  85. Smith A, Buchinsky FJ, Post JC. Eradicating chronic ear, nose, and throat infections: a systematically conducted literature review of advances in biofilm treatment. Otolaryngol Head Neck Surg 2011;144:338–347 [CrossRef][PubMed]
    [Google Scholar]
  86. Krespi YP, Stoodley P, Hall-Stoodley L. Laser disruption of biofilm. Laryngoscope 2008;118:1168–1173 [CrossRef][PubMed]
    [Google Scholar]
  87. Bakaletz LO. Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media. Paediatr Respir Rev 2012;13:154–159 [CrossRef][PubMed]
    [Google Scholar]
  88. Smith AW. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?. Adv Drug Deliv Rev 2005;57:1539–1550 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000810
Loading
/content/journal/jmm/10.1099/jmm.0.000810
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error